Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer

European Journal of Cancer

Volumn 46, Issue 12, 2010, Pages 2314-2323

  Grimm, Martin ^a   Kim, Mia ^a   Rosenwald, Andreas ^a   Von Rahden, Burkhard ^a   Tsaur, Igor ^b   Meier, Eva ^a   Heemann, Uwe ^c   Germer, Christoph Thomas ^a   Gasser, Martin ^a   Waaga Gasser, Ana Maria ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Colorectal carcinoma; Death receptor expression; Tumour escape mechanisms

Indexed keywords

CD8 ANTIGEN; DEATH RECEPTOR 4; FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURGERY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; AGED; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 77955711598     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.025     Document Type: Article

References (29)

1. C.C. Compton, L.P. Fielding, and L.J. Burgart Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 2000 979 994
2. F. Balkwill Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 2002 135 141
3. J.C. Reed Apoptosis-targeted therapies for cancer Cancer Cell 3 2003 17 22
4. Y. Huang, and M.S. Sheikh TRAIL death receptors and cancer therapeutics Toxicol Appl Pharmacol 224 2007 284 289
5. V. Huber, S. Fais, and M. Iero Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape Gastroenterology 128 2005 1796 1804
6. M. Giovarelli, P. Musiani, and G. Garotta A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions J Immunol 163 1999 4886 4893
7. S. Koyama, N. Koike, and S. Adachi Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor J Cancer Res Clin Oncol 128 2002 73 79
8. J. O'Connell, M.W. Bennett, G.C. O'Sullivan, J.K. Collins, and F. Shanahan The Fas counterattack: cancer as a site of immune privilege Immunol Today 20 1999 46 52
9. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17-22.
10. H. Walczak, R.E. Miller, and K. Ariail Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 1999 157 163
11. A. Ashkenazi, R.C. Pai, and S. Fong Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155 162
12. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th ed. In: Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
13. F.L. Greene TNM staging for malignancies of the digestive tract: 2003 changes and beyond Semin Surg Oncol 21 2003 23 29
14. Y. Gavrieli, Y. Sherman, and S.A. Ben-Sasson Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol 119 1992 493 501
15. B. Ansari, P.J. Coates, B.D. Greenstein, and P.A. Hall In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states J Pathol 170 1993 1 8
16. A. Ashkenazi, and V.M. Dixit Apoptosis control by death and decoy receptors Curr Opin Cell Biol 11 1999 255 260
17. D. Kagi, F. Vignaux, and B. Ledermann Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity Science 265 1994 528 530
18. K. Hallermalm, A. De Geer, R. Kiessling, V. Levitsky, and J. Levitskaya Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes Cancer Res 64 18 2004 6775 6782
19. V. Poulaki, C.S. Mitsiades, and N. Mitsiades The role of Fas and FasL as mediators of anticancer chemotherapy Drug Resist Updat 4 2001 233 242
20. M.W. Bennett, J. O'Connell, and G.C. O'Sullivan The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J Immunol 160 1998 5669 5675
21. A.E. Ryan, F. Shanahan, J. O'Connell, and A.M. Houston Fas ligand promotes tumor immune evasion of colon cancer in vivo Cell Cycle 5 2006 246 249
22. E.K. Rowinsky Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents J Clin Oncol 23 36 2005 9394 9407
23. H.A. Elrod, and S.Y. Sun Modulation of death receptors by cancer therapeutic agents Cancer Biol Ther 7 2 2008 163 173
24. D. Mahalingam, E. Szegezdi, M. Keane, S. Jong, and A. Samali TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35 3 2009 280 288
25. C.M. van Geelen, J.L. Westra, and E.G. de Vries Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients J Clin Oncol 24 2006 4998 5004
26. S. Koyama, N. Koike, and S. Adachi Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor J Cancer Res Clin Oncol 128 2 2002 73 79
27. N. Kassouf, and M.H. Thornhill Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers Oral Oncol 44 7 2008 672 682
28. T. Oshikiri, M. Miyamoto, and T. Morita Tumor-associated antigen recognized by the 22-1-1 monoclonal antibody encourages colorectal cancer progression under the scanty CD8+ T cells Clin Cancer Res 12 2006 411 416
29. Y. Zhang, and B. Zhang TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5 Mol Cancer Res 6 2008 1861 1871